MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Signal Genetics Company Profile (NASDAQ:SGNL)

Consensus Ratings for Signal Genetics (NASDAQ:SGNL) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.44 (601.53% upside)

Analysts' Ratings History for Signal Genetics (NASDAQ:SGNL)
Show:
DateFirmActionRatingPrice TargetActions
1/26/2016AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016HC WainwrightInitiated CoverageBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016Rodman & RenshawInitiated CoverageBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2015Chardan CapitalReiterated RatingBuy$2.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Signal Genetics (NASDAQ:SGNL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/16/2016Q116($0.28)($0.26)$645.00 million$808.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2016Q415($0.36)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.39)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.36)($0.45)$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2015($0.39)($1.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.05)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Signal Genetics (NASDAQ:SGNL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Signal Genetics (NASDAQ:SGNL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Signal Genetics (NASDAQ:SGNL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/20/2015Samuel D. RiccitelliCEOBuy14,000$0.79$11,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Signal Genetics (NASDAQ:SGNL)
DateHeadline
06/23/16 03:06 PMSIGNAL GENETICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial -
06/16/16 04:28 PMSIGNAL GENETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/30/16 06:32 PMAfter Last Week What Do Analysts Think Of Signal Genetics, Inc. (SGNL) - Share Trading News - After Last Week What Do Analysts Think Of Signal Genetics, Inc. (SGNL)Share Trading News09/23/2015 – Signal Genetics, Inc. had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 2.75 price target on the stock. The share price of Signal Genetics, Inc. (SGNL) was up +3.39% during the last trading session, with a ...Signal Genetics Incorporated (NASDAQ:SGNL) Sellers Covered 74.62% of Their ShortsFranklin Independentall 2 news articles »
05/26/16 07:30 AMSignal Genetics Receives Extension to Comply with Nasdaq Continued Listing Requirement - [GlobeNewswire] - CARLSBAD, Calif., May 26, 2016-- Signal Genetics, Inc., a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed ...
05/25/16 07:30 AMSignal Genetics to Present at the LD Micro Invitational - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / May 25, 2016 / Signal Genetics, Inc. (NASDAQ: SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services ...
05/23/16 11:14 AMSignal Genetics, Inc. :SGNL-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/16/16 07:30 AMSignal Genetics Highlights Recent Achievements and Reports First Quarter 2016 Financial Results - [GlobeNewswire] - CARLSBAD, Calif., May 16, 2016-- Signal Genetics, Inc., a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed ...
03/21/16 03:41 PMSIGNAL GENETICS, INC. Files SEC form 10-K, Annual Report -
03/21/16 10:57 AMSignal Genetics, Inc. :SGNL-US: Earnings Analysis: 2015 By the Numbers -
03/16/16 03:05 PMSignal Genetics Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2015 Financial Results - [GlobeNewswire] - CARLSBAD, Calif., March 16, 2016-- Signal Genetics, Inc., a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed ...
03/16/16 06:07 AMQ4 2015 Signal Genetics Inc Earnings Release - After Market Close -
03/10/16 07:30 AMSignal Genetics to Host 2015 Annual Corporate Update Call - [GlobeNewswire] - CARLSBAD, Calif., March 10, 2016-- Signal Genetics, Inc., a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed ...
02/26/16 09:49 AMBrokerage Analyst Buys: Golar LNG Limited (NASDAQ:GLNG), Oncothyreon Inc. (NASDAQ:ONTY), Evoke Pharma, Inc ... - RiversideGazette.com - Brokerage Analyst Buys: Golar LNG Limited (NASDAQ:GLNG), Oncothyreon Inc. (NASDAQ:ONTY), Evoke Pharma, Inc ...RiversideGazette.comShares of Signal Genetics, Inc. (NASDAQ:SGNL) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $2.6300 price target according to the covering analysts.
02/26/16 09:49 AMSignal Genetics Incorporated (NASDAQ:SGNL) Shorts Decreased by 4.99% After Short Covering - RiversideGazette.com - Signal Genetics Incorporated (NASDAQ:SGNL) Shorts Decreased by 4.99% After Short CoveringRiversideGazette.comThe short interest to Signal Genetics Incorporated's float is 5.81%. The stock decreased 5.66% or $0.03 on February 25, hitting $0.5. About 67,296 shares traded hands or 34.55% up from the average. Signal Genetics Inc (NASDAQ:SGNL) has declined ...
02/03/16 11:54 AMSignal Genetics, Inc. (SGNL) - Signal Genetics, Inc., a commercial stage molecular genetic diagnostic company, focuses on providing diagnostic services that assist physicians in decision making for the care of patients suffering from cancer. The company offers Myeloma Prognostic Risk ...
01/12/16 10:50 AMSignal Genetics, Inc. (NASDAQ: SGNL) Begins Patient Study for its MyPRS(R) Assay - [Accesswire] - NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Signal Genetics, Inc. (NASDAQ: SGNL) has entered into an agreement with the University of Texas MD Anderson Cancer Center to further validate the clinical ...
01/08/16 06:11 AMCoverage initiated on Signal Genetics by Rodman & Renshaw -
01/06/16 08:03 AMSignal Genetics and MD Anderson Cancer Center Enter Into Sponsored Research Agreement - [at noodls] - CARLSBAD, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative ...
12/29/15 01:59 PMWhy Aegis Capital Loves Signal Genetics -
12/08/15 12:18 PMSIGNAL GENETICS, INC. Financials -
11/30/15 04:26 PMSIGNAL GENETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand -
11/24/15 07:43 AMSignal Genetics to Present at the 8th Annual LD Micro Main Event - [at noodls] - CARLSBAD, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative ...
11/13/15 03:02 PMSIGNAL GENETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi -
11/12/15 03:26 PMSignal Genetics Highlights Recent Achievements and Reports Third Quarter 2015 Financial Results - [at noodls] - CARLSBAD, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative ...
11/05/15 07:50 AMSignal Genetics' MyPRS(R) Highlighted in the Journal Leukemia - [at noodls] - CARLSBAD, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services ...
10/20/15 07:52 AMSignal Genetics Expands Reimbursement of MyPRS(R) With Additional Preferred Provider Organization Agreements - [at noodls] - Signal Genetics Expands Reimbursement of MyPRS(R) With Additional Preferred Provider Organization Agreements
10/02/15 08:00 AMUpdated Presentation Time: Signal Genetics to Present at the 2015 Aegis Growth Conference - [at noodls] - CARLSBAD, Calif., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative ...
09/24/15 07:58 AMSignal Genetics Granted First European Patent for MyPRS(R) - [at noodls] - CARLSBAD, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative ...
09/24/15 07:36 AMSIGNAL GENETICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
About Signal Genetics

Signal Genetics logoSignal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SGNL
  • CUSIP:
Key Metrics:
  • Previous Close: $0.49
  • 50 Day Moving Average: $0.56
  • 200 Day Moving Average: $0.58
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $5.25M
  • Current Quarter EPS Consensus Estimate: $-0.74 EPS
Additional Links:
Signal Genetics (NASDAQ:SGNL) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha